Research Areas

In a deal worth potentially just over a half billion dollars, SGX Pharmaceuticals is embarking on a license and collaboration agreement with Novartis that focuses on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia (CML).

California Institute for Regenerative Medicine hears issues raised over stem cell line licenses owned by WARF as well as prospective royalty schedules for funded research.

Dr. Mike Gilson and colleagues at the University of Maryland Biotechnology Institute (UMBI) developed the Binding Database (BindingDB), a public, web-accessible repository of binding affinities between small molecules and protein drug targets. At present, the repository is home to approximately 14,000 measurements of about 8,000 compounds and 60 targets.

Ingenuity Systems and Inpharmatica Ltd. bring the benefit of two distinctly different products by offering the ability to use in tandem their Blu-Chip and Ingenuity Pathway Analysis (IPA) offerings.

Eli Lilly & Co. pilot study utilizes Optimata’s “virtual patient” technology to assist in the development of clinical trials for a novel anti-cancer cytotoxic compound.

IBM, array-microscope technology developer DMetrix and BioImagene, recently announced that ultra-rapid whole-slide imaging and large-scale scientific image management have been integrated for first time.

Molecular Devices Corp. acquired the laser capture microdissection (LCM)-related business of Arcturus Bioscience for $10 million in cash, a strategic acquisition that expands Molecular Devices’ life sciences product portfolio to include complete systems and reagents for LCM.